<DOC>
	<DOC>NCT01736189</DOC>
	<brief_summary>In the usual clinical setting, patients with Rheumatoid Arthritis who receive adalimumab (Humira®) and high-dose Methotrexate (≥12 mg/week) will be investigated prospectively for effectiveness according to Disease Activity Score 28, modified Total Sharp Score, and other measures, as well as safety in terms of the incidence and pattern of occurrence of adverse drug reactions.</brief_summary>
	<brief_title>Special Investigation in Patients With Rheumatoid Arthritis (Combo Study; Adalimumab With High Dose Methotrexate)</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>The subjects of this study are RA patients and to whom adalimumab is administered. They should be satisfying the following conditions: Disease duration of RA ≤2 years MTX administration ≥3 months Dose of MTX ≥12mg/week DAS28CRP &gt;3.2 Patients who have been previously treated with biologics (including TNF inhibitors others)</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Rheumatoid arthritis</keyword>
</DOC>